---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045557"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:01:59.447991+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%

## Summary
- Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.
- Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.
- Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.
- Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.
- Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025.

## SEC filing metadata
- accession: 0001104659-25-045557
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/0001104659-25-045557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/tm2514334d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045557
- JSON: https://secwatch.observer/filing/0001104659-25-045557.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045557.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.